CAII/VII-IN-1 

CAII/VII-IN-1 is an orally active hCA II (K_I = 12.3 nM), and hCA VII (K_I = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy^[1].

CAII/VII-IN-1 (Compound 16d) is safe at the given concentration in Vero cells (IC₅₀ = 59.7 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CAII/VII-IN-1 (200 mg/kg, oral gavage, once) produces pronounced anti-convulsant and anti-epileptogenic effects in Pilocarpine-induced mice, as manifested by a two-fold increase in seizure onset latency, a substantial reduction in seizure severity, and the restoration of hippocampal homeostasis ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

639.11

C₂₇H₂₃ClN₈O₅S₂

3085155-69-4

ClC1=CC=C(C=C1)C2=NN(C=C2/C=N/NC(C3=C(N(N=N3)C4=CC=C(C=C4)S(N)(=O)=O)C)=O)C5=CC=C(C=C5)S(C)(=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. ie Y, et al. Development of potent glutathione transferase Omega-1 inhibitors with applications in inflammation and cancer therapy. Eur J Med Chem. 2025 Dec 5;299:118072.  [Content Brief]